Health & Biotech Weed Week: An Aussie medicinal cannabis farm for sale and crypto ATMs in weed dispensaries July 15, 2022 ECS is selling its medicinal cannabis farm in Tasmania to focus on medicinal cannabis production at its Victorian facility. How Nutritional Growth Solutions expanded from three products to 22 in a year July 14, 2022 Special Report: Nutritional Growth Solutions has enacted a three-point strategy for growth, and it’s already proving a winner. ASX Health Stocks: Another Aussie biotech gets attention in the US with a pending patent July 14, 2022 Cynata Therapeutics (ASX:CYP), has just received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). ASX Health Stocks: Upcoming clinical trials for these two ASX-listed neuro disease biotechs July 12, 2022 Neurological disorders specialist Neuren Pharmaceuticals (ASX: NEU) says that its Phase 2 clinical trial of NNZ-2591 is open for enrolment. ASX Health Stocks: Lumos down 65pc on FDA rejection; and is Hexima belly-up after Phase 2 readout? July 11, 2022 Some unexpected news on ASX health stocks today. Lumos said FebriDX has been rejected by the FDA, while Hexima announces… ASX Health Stocks: MXC tests positive in South Africa for COVID-19; NTI high on cannabis v autism in kids July 8, 2022 MGC Pharma to go Phase 2 on COVID-19 in South Africa Neurotech says cannabis strain works well in children with… Neurotech study says cannabis could be key to helping kids on the spectrum reach potential July 8, 2022 Special Report: Neurotech has released promising results from a world first study of a medicinal cannabis product in children which… ASX Health Stocks: FDA to expedite submission for Botanix’s sweaty armpits gel July 7, 2022 Botanix's FDA submission gets accelerated Release extends contract with Medgate to use the ResAppDx platform Cyclopharm's Technegas is used ahead… Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit July 7, 2022 McKinsey showed that VCs ploughed US$35 billion into biotechs doing certain programs. Which ASX biotechs are doing similar programs? ASX Health Stocks: ResApp gets FDA nod, while Japan grants Immutep a patent July 6, 2022 ResApp Health (ASX:RAP) announced that SleepCheckRx has received 510(k) clearance as a medical device from the US FDA. Next» « Previous